StreetInsider.com News Articles

Form 4 Cadrenal Therapeutics, For: Oct 09 Filed by: Pham Quang X

Tue, 13 Oct 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20261013/27182082.html

Form 4 Cadrenal Therapeutics, For: Oct 09 Filed by: Golden Lee Scott

Tue, 13 Oct 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20261013/27182081.html

Form 4 Cadrenal Therapeutics, For: Oct 09 Filed by: MURPHY JOHN RAYMOND

Tue, 13 Oct 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20261013/27182080.html

Form 4 Cadrenal Therapeutics, For: Oct 09 Filed by: Cole Jeffrey Scott

Tue, 13 Oct 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20261013/27182078.html

Form 4 Cadrenal Therapeutics, For: Oct 09 Filed by: WILSON GLYNN

Tue, 13 Oct 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20261013/27182072.html

Form S-8 Cadrenal Therapeutics,

Thu, 08 Oct 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20261008/27167650.html

Form 8-K Cadrenal Therapeutics, For: Oct 07

Wed, 07 Oct 2026 09:24:00 -0400

si-local-file:///var/storage/secattach/20261007/27159082.html

Cadrenal Therapeutics launches strategic review, hires Tungsten Advisors

Wed, 07 Oct 2026 07:03:49 -0400

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) said its board of directors has initiated a formal strategic process to evaluate potential transactions involving the company and its drug portfolio, according to a press release.

The company has retained Tungsten Advisors as its exclusive financial advisor for the process. Cadrenal said it will consider a range of potential transactions, including licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, and business combinations.

The review covers Cadrenal's clinical- and development-stage programs, including CAD-1005, tecarfarin, frunexian, and CAD-2000. CAD-1005 is a 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia, a thrombotic disorder. The program has

Cadrenal Therapeutics launches strategic review, hires Tungsten Advisors

Wed, 07 Oct 2026 07:03:49 -0400

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Wed, 07 Oct 2026 07:00:00 -0400

Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005
Cadrenal has received strong interest from potential strategic partners
Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions

PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Wed, 07 Oct 2026 07:00:00 -0400

Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005
Cadrenal has received strong interest from potential strategic partners
Cadrenal will explore all strategic alternatives including corporate partnerships and other strategic transactions

Form 8-K Cadrenal Therapeutics, For: Sep 24

Tue, 29 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260929/27122445.html

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

Mon, 21 Sep 2026 16:30:00 -0400

PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

Mon, 21 Sep 2026 16:30:00 -0400

Company Webcast

The webcast presentation will take place at 10:15 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at

Form 10-Q Cadrenal Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921922.html

Form 10-Q Cadrenal Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921922.html

Form 8-K Cadrenal Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921849.html

Form 8-K Cadrenal Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26921849.html

Cadrenal Therapeutics, Inc. (CVKD) Tops Q2 EPS by 27c

Thu, 13 Aug 2026 16:17:03 -0400

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.14), $0.27 better than the analyst estimate of ($1.41).

For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Thu, 13 Aug 2026 16:15:00 -0400

PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update on the launch of a structured strategic partnering process following significant clinical, regulatory, and portfolio progress across its Cardiac Acute Critical Care Franchise.